8-K current report · filed Oct 29, 2026

Inmune Bio, Inc. (INMB) 8-K Current Report: October 29, 2026

Item 1.01Item 7.01Item EX-99.1Item 3.02INMB overview

Short answer

Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 3.02 (Unregistered Sales of Equity Securities). $4.5M gross capital raise through 3M shares at $1.50, strengthening funding before fees and expenses.

Inmune Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $4.5M gross capital raise through 3M shares at $1.50, strengthening funding before fees and expenses
  • Warrants for 3M additional shares at $1.65, creating potential dilution through April 27, 2032
  • Warrant exercises begin April 27, 2027, with 9.99% ownership cap adjustable up to 19.99%
  • Placement agent compensation: 7.0% of gross proceeds, plus up to $100,000 legal and $25,000 non-accountable expenses
  • Resale registration required within 30 days, potentially increasing future trading supply and dilution overhang

Item 3.02 · Unregistered Sales of Equity Securities

  • Unregistered Common Warrants and underlying shares issued under Section 4(a)(2) private-placement exemption
  • Securities issued to an accredited investor or qualified institutional buyer
  • Resale restrictions remain until registration or another Securities Act exemption applies
  • Potential future dilution if warrant holders exercise the Common Warrants

Item 7.01 · Regulation FD Disclosure

  • October 28, 2026 press release announced pricing of Inmune Bio’s offering
  • Offering terms and investor dilution implications require review of Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • $4.50 million gross financing through 3,000,000 shares and warrants for 3,000,000 shares
  • Warrant exercise price $1.65, exercisable after six months and expiring 5.5 years after issuance
  • Equity issuance creates immediate dilution, with additional potential dilution from warrant exercises
  • Proceeds designated for working capital and general corporate purposes, supporting ongoing clinical development
  • Planned CORDStrom and XPro1595 milestones remain dependent on additional funding and regulatory approvals

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inmune Bio, Inc. 8-K filings

Get the next INMB 8-K as it lands

Follow INMB for push alerts, or ask the research agent what this filing means.